Table 2.
Baseline clinical characteristics of the patients of intrahepatic bile duct adenocarcinoma and sarcomatoid cholangiocarcinoma n (%)
| Adenocarcinoma | Sarcomatoid | P value | ||
| Gender | Male | 155 (71.8) | 9 (81.8) | 0.732 |
| Female | 61 (28.2) | 2 (18.2) | ||
| Age | < 60 | 73 (33.8) | 5 (45.5) | 0.518 |
| ≥ 60 | 143(66.2) | 6 (54.5) | ||
| Abdominal pain | No | 106 (49.1) | 1 (9.1) | 0.011 |
| Pain | 110 (50.9) | 10 (90.9) | ||
| Fever | No | 195 (90.3) | 7 (63.6) | 0.022 |
| Fever | 21 (9.7) | 4 (36.4) | ||
| Jaundice | No | 199 (92.1) | 11 (100.0) | 1.000 |
| Jaundice | 17 (7.9) | 0 (0.0) | ||
| Weight loss | No | 201 (93.1) | 10 (90.9) | 0.561 |
| Weight loss | 15 (6.9) | 1 (9.1) | ||
| GB stone | No | 164 (75.9) | 8 (72.7) | 0.730 |
| GB stone | 52 (24.1) | 3 (27.3) | ||
| Hepatitis | No | 190 (88.0) | 7 (63.6) | 0.063 |
| CHB | 21 (9.7) | 3 (27.3) | ||
| CHC | 5 (2.3) | 1 (9.1) | ||
| LC | No | 183 (84.7) | 6 (54.5) | 0.022 |
| LC | 33 (15.3) | 5 (45.5) | ||
| Serum CEA | < 5 ng/mL | 123 (56.9) | 10 (90.9) | 0.029 |
| ≥ 5 ng/mL | 93 (43.1) | 1 (9.1) | ||
| Serum CA19-9 | < 37 U/mL | 64 (29.6) | 6 (54.5) | 0.098 |
| ≥ 37 U/mL | 152 (70.4) | 5 (45.5) | ||
| Main mass | Single | 145 (67.1) | 6 (54.5) | 0.513 |
| Multiple | 71 (32.9) | 5 (45.5) | ||
| Mass size | < 5 cm | 90 (41.7) | 1 (9.1) | 0.054 |
| ≥ 5 cm | 126 (58.3) | 10 (90.9) | ||
| LN metastasis | No | 84 (38.9) | 1 (9.1) | 0.057 |
| LN meta. | 132 (61.1) | 10 (90.9) | ||
| Distant metastasis | No | 140 (64.8) | 4 (36.4) | 0.104 |
| Distant meta. | 76 (35.2) | 7 (63.6) | ||
| TNM stage | I or II | 76 (35.2) | 0 (0.0) | 0.018 |
| III or IV | 140 (64.8) | 11 (100.0) | ||
CA19-9: Carbohydrate antigen 19-9; CEA: Carcinoembryonic antigen; CHB: Chronic hepatitis B; CHC: Chronic hepatitis C; LC: Liver cirrhosis; LN: Lymph node.